Renal Cancer

Oncogenic TFE3 fusions drive OXPHOS and confer metabolic vulnerabilities in translocation renal cell carcinoma. February 11, 2025

A Fully Automated Artificial Intelligence-Based Approach to Predict Renal Function after Radical or Partial Nephrectomy. February 11, 2025

Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study. February 11, 2025

Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis. February 10, 2025

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis. February 10, 2025

Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series. February 10, 2025

Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery. February 10, 2025

Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma. February 7, 2025

New Mediastinal and Hilar Lymphadenopathy After Adjuvant Pembrolizumab in a Patient With Stage III Clear Cell Renal Cell Carcinoma. February 6, 2025

Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis. February 6, 2025

MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms. February 6, 2025

Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma. February 5, 2025

Surgical options for advanced renal cell carcinoma. February 5, 2025

Multicenter study of active surveillance for small renal masses: Real world practice pattern. February 5, 2025

Trend of cardiovascular mortality among metastatic renal cell cancer patients in the US from 2005 to 2020. February 4, 2025

Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study. February 4, 2025

Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear Cell Renal Cell Carcinoma. February 3, 2025

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial. February 3, 2025

Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers. January 31, 2025

Recurrence after surgery for clear cell and papillary renal cell carcinoma: Head-to head comparison of validated risk scores. January 31, 2025

Page 1 of 460